A future beyond
Type 1 Diabetes
We champion bold research and visionary scientists to get closer to a world where Type 1 Diabetes is no longer a daily burden.
Our beneficiaries
Progress today cure tomorrow
At the Bukhman Foundation, one of our core missions is to find a cure for people with Type 1 Diabetes (T1D). We believe that bold ideas and visionary leadership can get us there. By partnering with researchers who push boundaries and challenge conventional thinking, we aim to build a future where T1D no longer limits how people live, dream, and thrive.
Our approach to funding medical research is grounded in partnership, trust, and long-term ambition. We support cutting-edge science, promote open research, and encourage collaboration between leading experts and institutions across the globe.
Our pledge
£100m to transform lives
The Bukhman Foundation is pledging the UK’s largest philanthropic commitment to funding groundbreaking research into treatments and cures for Type 1 Diabetes.
What we’re supporting
The Bukhman Centre for Research Excellence in Type 1 Diabetes
Catalysing breakthroughs at Oxford to cure Type 1 Diabetes.
Project highlights
Expanding Type 1 Diabetes Care through PEN-Plus
A new three-year collaboration will support educational camps and peer networks for children and young people living with Type 1 Diabetes in rural sub-Saharan Africa.
New Website for the Bukhman Centre at the University of Oxford
A new online platform connecting researchers, patients, and families to accelerate collaborative research in Type 1 Diabetes.
Bukhman Foundation backs James Norton’s TCS London Marathon run for Breakthrough T1D
All donations will be double-matched to support type 1 diabetes research.
Who we partner with
We partner with leading researchers and institutions globally, supporting innovative, expert-led research that pushes scientific boundaries and aims for transformational impact. Our partners include University of Oxford, Cambridge University, Harvard University, Breakthrough T1D, T1D Fund and Diabetes UK.